KaydedilenlerDerginizi ekleyin

Dergiler / Archives of Current Medical Research / 2021 / Cilt: 2 - Sayı: 3

Non-Surgical Treatment Options for Peyronie’s Disease

Damla ÇINAR
Sedanur SARI
Hüseyin ALKAN
Kübra Buket AY
Enes BORCAKTEPE
Ahmet Yiğit DUYUM
Sude Sevcan FİLİKÇİ
Eren GENÇER
Çağla SENEM
Serhat SOYLU
Şeyma TUNA
Rabia TUNCER
Mehmet Emin YAZICI
Emre ALTINTAŞ
Murat GÜL
Sayfa
136–145
Yayın Tarihi
2021-09-22
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Food and Drug Administration) yet is clostridium collagenase histolikum, which is used in intraplaque injection, studies have shown that other methods also reduce curvature, pain, and plaque volume.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Peyronie’s disease, which occurs with the formation of a fibrous plaque in the tunica albuginea; is a disease that causes some physical problems such as bending and shortening of the penis.
📊
Temel Bulgular & Veri:There are surgical treatment methods of this disease as well as non-surgical treatment methods.
💡
Sonuç & Katkı:Food and Drug Administration) yet is clostridium collagenase histolikum, which is used in intraplaque injection, studies have shown that other methods also reduce curvature, pain, and plaque volume.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Peyronie’s Disease · Non-Surgical Treatment · Plaque.

Abstract

Peyronie’s disease, which occurs with the formation of a fibrous plaque in the tunica albuginea; is a disease that causes some physical problems such as bending and shortening of the penis. There are surgical treatment methods of this disease as well as non-surgical treatment methods. Non-surgical treatment methods, which are grouped under six headings: oral treatments, topical treatments, traction and vacuum treatments, shock wave therapy, intraplate injection treatments, and experimental treatments, can be preferred in cases where the symptoms are not very advanced because they provide advantages in terms of ease of application, accessibility, and cost. Although the only non-surgical treatment method approved by the FDA (U.S. Food and Drug Administration) yet is clostridium collagenase histolikum, which is used in intraplaque injection, studies have shown that other methods also reduce curvature, pain, and plaque volume.

🔖

Bu Makaleye Atıf Yap

ÇINAR, D., SARI, S., ALKAN, H., AY, K. B., BORCAKTEPE, E., DUYUM, A. Y., FİLİKÇİ, S. S., GENÇER, E., SENEM, Ç., SOYLU, S., TUNA, Ş., TUNCER, R., YAZICI, M. E., ALTINTAŞ, E., GÜL, M. (2021). Non-Surgical Treatment Options for Peyronie’s Disease. Archives of Current Medical Research, Cilt: 2 - Sayı: 3, 136–145. https://ajindex.com/articles/850286

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (13)

  1. Ory J, MacDonald L, Langille G. Noninvasive Treatment Options for Peyronie’s Disease. Sex Med Rev. 2020;8(4):603-614
  2. Paulis G, Romano G, Paulis A. Prevalence, psychological impact, and risk factors of erectile dysfunction in patients with Peyronie’s disease: a retrospective analysis of 309 cases. Res Rep Urol. 2016;8:95-103
  3. Sasso F, Gulino G, Falabella R, D’Addessi A, Sacco E, D’Onofrio A et al. Peyronie’s disease: lights and shadows. Urol Int. 2007;78(1):1-9
  4. Patel DP, Christensen MB, Hotaling JM, Pastuszak AW. A review of inflammation and fibrosis: implications for the pathogenesis of Peyronie’s disease. World J Urol. 2020;38(2):253-261
  5. Armağan A, Soyupek S, Hoşcan B. Peyronie hastalığının medikal tedavisindeki yenilikler. Androloji Bülteni. 2004;6(17):93-98 6. Hussein AA, Alwaal A, Lue TF. All about Peyronie’s disease. Asian J Urol. 2015;2(2):70-78
  6. Hellstrom WJ, Bivalacqua TJ. Peyronie’s disease: etiology, medical, and surgical therapy. J Androl. 2000;21(3):347-54
  7. Mynderse LA, Monga M. Oral therapy for Peyronie’s disease. Int J Impot Res. 2002;14(5):340-4
  8. Akkus E, Yıldırım Ö. Peyronie hastalığı. In: Doğan HS, editor. Ürolojik Cerrahi Kitabı. İstanbul:Galenos; 2020. p. 289-319 10. Prieto Castro RM, Leva Vallejo ME, Regueiro Lopez JC, Anglada Curado FJ, Alvarez Kindelan J, Requena Tapia MJ. Combined treatment with vitamin E and colchicine in the early stages of Peyronie’s disease. BJU Int. 2003;91(6):522-4
  9. Vernet D, Ferrini MG, Valente EG, Magee TR, Bou-Gharios G, Rajfer J et al. Effect of nitric oxide on the differentiation of fibroblasts into myofibroblasts in the Peyronie’s fibrotic plaque and in its rat model. Nitric Oxide. 2002;7(4):262-76
  10. Valente EG, Vernet D, Ferrini MG, Qian A, Rajfer J, Gonzalez-Cadavid NF. L-arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie’s fibrotic plaque and related fibroblast cultures. Nitric Oxide. 2003;9(4):229-44
  11. Ferrini MG, Kovanecz I, Nolazco G, Rajfer J, Gonzalez-Cadavid NF. Effects of long-term vardenafil treatment on the development of fibrotic plaques in a rat model of Peyronie’s disease. BJU Int. 2006;97(3):625-33
  12. Ozturk U, Yesil S, Goktug HN, Gucuk A, Tuygun C, Sener NC et al. Effects of sildenafil treatment on patients with Peyronie’s disease and erectile dysfunction. Ir J Med Sci. 2014;183(3):449-53
  13. Chung E, Deyoung L, Brock GB. The role of PDE5 inhibitors in penile septal scar remodeling: assessment of clinical and radiolo